Cargando…
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
SIMPLE SUMMARY: Poly(ADP-ribose) polymerase (PARP) inhibitors, which are medications approved to treat various solid tumors, including breast, prostate, ovarian, and prostate cancers, are being examined in hematological malignancies. This review summarizes the potential role of PARP inhibitors in th...
Autores principales: | Csizmar, Clifford M., Saliba, Antoine N., Swisher, Elizabeth M., Kaufmann, Scott H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699275/ https://www.ncbi.nlm.nih.gov/pubmed/34945003 http://dx.doi.org/10.3390/cancers13246385 |
Ejemplares similares
-
Double-edged sword.
Publicado: (1994) -
HDAC inhibitors and immunotherapy; a double edged sword?
por: Kroesen, Michiel, et al.
Publicado: (2014) -
Seatbelt: A Double-Edged Sword
por: Raychaudhuri, P., et al.
Publicado: (2012) -
The double-edged sword of evolution
por: Kruzel-Davila, Etty, et al.
Publicado: (2017) -
A double-edged sword
por: Vandebotermet, Martijn, et al.
Publicado: (2020)